Clinical Trials Logo

Clinical Trial Summary

The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05201703
Study type Interventional
Source University of Florida
Status Recruiting
Phase Phase 4
Start date March 9, 2022
Completion date December 15, 2023

See also
  Status Clinical Trial Phase
Completed NCT02426047 - Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy N/A
Withdrawn NCT00559169 - Verapamil and Catamenial Epilepsy N/A
Completed NCT00465517 - A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures Phase 2